Arkansas Healthcare Report: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Arkansas Healthcare Report.

January 2026

Mo	Tu	We	Th	Fr	Sa	Su
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

February 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

March 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

Press releases published on February 20, 2026

Feb. 20, 2026

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares

GlobeNewswire

Feb. 20, 2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

Feb. 20, 2026

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

Feb. 20, 2026

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

Feb. 20, 2026

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

Feb. 20, 2026

Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates

GlobeNewswire

Feb. 20, 2026

Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option

GlobeNewswire

Feb. 20, 2026

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

GlobeNewswire

Feb. 20, 2026

ADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1/2 Clinical Data and Phase 3 Design at the 2026 AAAAI Annual Meeting

GlobeNewswire

Feb. 20, 2026

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

GlobeNewswire

Feb. 20, 2026

Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development

GlobeNewswire

Feb. 20, 2026

20/20 BioLabs to Host Virtual Investor Webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time

GlobeNewswire

Feb. 20, 2026

PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval

GlobeNewswire

Feb. 20, 2026

CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference

GlobeNewswire

Feb. 20, 2026

CDT Acquires Strategic Stake in Sarborg to Transform its AI-Driven Asset Strategy

GlobeNewswire

Feb. 20, 2026

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Announces Expanded IP Coverage, Strengthening Position in Biotech Evolution

GlobeNewswire

Feb. 20, 2026

AltruBio Announces Formation of Inflammatory Bowel Disease Clinical Advisory Board

GlobeNewswire

Feb. 20, 2026

Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections

GlobeNewswire

Feb. 20, 2026

Lifeward Announces Reverse Share Split

GlobeNewswire

Feb. 20, 2026

Syncx Accelerates the Future of Locums Staffing with Major Platform Enhancements and Rapid AI Expansion

GlobeNewswire